Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Upstream Bio (UPB) Common Equity (2023 - 2025)

Upstream Bio has reported Common Equity over the past 3 years, most recently at $339.8 million for Q4 2025.

  • Quarterly results put Common Equity at $339.8 million for Q4 2025, down 27.69% from a year ago — trailing twelve months through Dec 2025 was $339.8 million (down 27.69% YoY), and the annual figure for FY2025 was $339.8 million, down 27.69%.
  • Common Equity for Q4 2025 was $339.8 million at Upstream Bio, down from $378.6 million in the prior quarter.
  • Over the last five years, Common Equity for UPB hit a ceiling of $469.9 million in Q4 2024 and a floor of -$160.3 million in Q3 2024.
  • Median Common Equity over the past 3 years was $113.8 million (2023), compared with a mean of $136.7 million.
  • Peak annual rise in Common Equity hit 481.6% in 2024, while the deepest fall reached 42.87% in 2024.
  • Upstream Bio's Common Equity stood at -$123.1 million in 2023, then surged by 481.6% to $469.9 million in 2024, then decreased by 27.69% to $339.8 million in 2025.
  • The last three reported values for Common Equity were $339.8 million (Q4 2025), $378.6 million (Q3 2025), and $408.7 million (Q2 2025) per Business Quant data.